The National Institutes of Health (NIH) Clinical Center in Bethesda, MD, intends to award a sole source contract to Takara Bio USA Inc. for 15 vials of RetroNectin® GMP grade reagent. This reagent is critical for manufacturing cellular therapy products used in over 50 intramural clinical trials at the Center for Cellular Engineering. Takara Bio USA is the sole manufacturer, and substitution is not permissible without revalidation and regulatory delays that could risk patient care. No budget amount is specified, and this notice is for informational purposes only, not a request for quotations. Interested parties may submit a capability statement by May 14, 2026, to demonstrate their ability to meet the requirement.